Sponsor: Roswell Park Cancer Institute
Sponsor Study ID: URCC-21038
Study Title: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti PD 1/anti PD L1 Immunotherapy in a Community Oncology Setting
CTO #: 103653
NCT Number: NCT05364086
Phase: N/A
Protocol Type: Other
Age Group: Adults
Disease Sites: Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites
Study Objectives: This is a Prospective Observational Cohort Study, designed specifically to investigate racial differences in toxicities and treatment outcomes of cancer patients treated with immune checkpoint inhibitors (ICIs).